Brief description of study

COVID-19 is due to an infection by the beta-coronavirus SARS-CoV2. This will be a randomized, double-blind, placebo-controlled study. Following signature of the informed consent form, approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo (1:1 allocation ratio) for 30 days. Colchicine is an anti-inflammatory drug that has been used for more than 2000 years to treat other inflammatory conditions, such as gout. We know that in COVID-19, people get severely ill partly due to the body’s overly robust immune response to the virus. We also know that colchicine dampens some parts of that type of immune response. Therefore, we want to determine if given early in the course of infection, colchicine can prevent hospitalizations, lung complications, and death related to COVID-19. The primary objective of this study is to determine whether short-term treatment with colchicine reduces the rate of death and lung complications related to COVID-19. The secondary objective is to determine the safety of treatment with colchicine in this patient population. If you are above the age of 40 years and have been diagnosed with or suspect you have COVID-19 in the last 36 hours, and are interested in participating, please email us at

Clinical Study Identifier: s20-00421 Identifier: NCT04322682
Principal Investigator: Binita Shah.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.